Gastrointestinal complications of nonsteroidal antiinflammatory drugs and low-dose aspirin;Complications gastro-intestinales des anti-inflammatoires non stéroïdiens et de l'aspirine à faible dose

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 5, 2003, Pages 498-510

  Thiéfin, Gérard ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SULINDAC; VALDECOXIB;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON ISCHEMIA; COLON STENOSIS; COLON ULCER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG MECHANISM; DYSPEPSIA; EDEMA; ENTERITIS; ENTEROPATHY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; HYPERTENSION; INTESTINE PERFORATION; INTESTINE STENOSIS; MALABSORPTION; REVIEW; RISK FACTOR;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DECISION TREES; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PATIENT SELECTION; PEPTIC ULCER; RISK ASSESSMENT; RISK FACTORS;

EID: 0037665159     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
2. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-35.
3. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
4. Faggionato D, Pigeon M, Naudin F, Sermet C, Fagnani F, Le Jeunne P. La diffusion des anti-COX2 dans la prescription des médecins. CREDES. Questions d'économie de la santé 2002; n° 60.
5. Capet C, Czernichow P, Dupas JL, Goria O, Gouérou H, Hochain P, et al. Hémorragies digestives hautes et aspirine à faible dose. Gastroenterol Clin Biol 2001;25:233-8.
6. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-38S.
7. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 1971;231:232-5.
8. Wallace JL, Back A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998;115:101-9.
9. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Int Med 2000;160:913-20.
10. Peskar BM. Cyclooxygenase inhibitor, a foe or a friend in the mucosal protection and repair. In: Cho CH, Wang JY eds. Gastrointestinal mucosal repair and experimental therapeutics. Front Gastrointest Res. Basel, Karger, 2002;25:166-79.
11. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 2001;44:437-50.
12. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Lacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxyde synthases. J Pharmacol Exp Ther 1994;271:1705-12.
13. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci 1999;96:7563-8.
14. Giuliano F, Ferraz JGP, Pereira R, de Nucci G, Warner TD. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol 2001;426:95-103.
15. Blain H, Boileau C, Lapicque F, Nedelec E, Loeuille D, Guillaume C, et al. Limitations of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 2002;53:255-65.
16. Lipsky P, Abramson SB, Crofford L, Dubois RN, Simon LS, Van de Putte LB. (The International COX-2 Study Group). The classification of cyclooxygenase inhibitors. J Rheumatol 1998;25:2298-303.
17. Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000;356:1373-4.
18. Graham DY. NSAID ulcers: prevalence and prevention. Mod Rheumatol 2000;10:2-7.
19. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ. III. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995;40:1345-50.
20. Giercksky KE, Husby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989;24(suppl 163):3-8.
21. Larkai EN, Lacey Smith J, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia In NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158162.
22. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
23. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987;28:527-32.
24. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;10:1078-88.
25. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum H, Fries JF. Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis - A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
26. Graham DY, Smith JL, Spjut HJ, Torres E. Gastric adaptation studies in humans during continuous aspirin administration. Gastroenterology 1988;95:327-33.
27. Caruso I, Bianchi-Porro G. Gastroscopic evaluation of anti-inflammatory agents. Br Med J 1980;1:75-8.
28. Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Int Med 1979;91:517-20.
29. Hawkey CJ, Wilson I, Naesdal J, Langström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 2002;51:344-50.
30. Bardhan KD, Bjamason I, Scott DL, Griffin WM, Fenn GC, Shield MJ, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastro-duodenal mucosal damage by misoprostol. Br J Rheumatol 1993;32:990-5.
31. Taha AS, Sturrock Russell RI. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut 1995;36:334-6.
32. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroentrology 1999;117:776-83.
33. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18:6-10.
34. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
35. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Int Med 1991;115:787-96.
36. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Facts and figures multiply, but do they addup? BMJ 1990;300:278-84.
37. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
38. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.
39. Thiéfin G. Toxicité de l'aspirine à faible dose: un problème sous-estimé et non résolu. Gastroenterol Clin Biol 2001;25:229-32.
40. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.
41. Weil J, Colin-jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
42. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric or buffered product. Lancet 1996;348:1413-6.
43. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-506.
44. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
45. McDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333-7.
46. Carson JF, Strom BL, Soper KA, West SL, Morse L. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Int Med 1987;147:85-8.
47. Thiéfin G. Faut-il rechercher et éradiquer Helicobacter pylori chez les malades traités ou devant être traités par aspirine ou anti-inflammatoires non stéroidiens. Gastroenterol Clin Biol 2003;27:415-26.
48. Huang JQ, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
49. Boulton-Jones JR, Hawkey CJ. Helicobacter pylori and peptic-ulcer disease. Lancet 2002;359:1943.
50. Santolaria S, Lanas A, Benito R, Perez-Aisa M, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor fro bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAIDs users. Aliment Pharmacol Ther 1999;13:1511-8.
51. Hawkey CJ, Naesdal J, Wilson I, Langström G, Swannell AJ, Peacock RA, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002;51:336-43.
52. Ekström P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A nordic multicenter study. Scand J Gastroenterol 1996;31:753-8.
53. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
54. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26.
55. Lancaster-Smith MJ, Jaderberg MR, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252-6.
56. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal antiinflammatory drug-associated gastric ulcers. Results of a double-blind, randomized, multicenter study. Arch Int Med 2000;160:1455-61.
57. Verdu EF, Armstrong D, Idström JP, Labenz J, Stolte M, Dorta G, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
58. Van Herwaarden MA, Samsom M, Van Nispen CH, Mulder PG, Smout AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999;13:731-40.
59. Labenz J, Tillenburg B, Peitz U, Verdu E, Stolte M, Börsch G, et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997;41:33-6.
60. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KE. Helicobacter pylori potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999;44:468-75.
61. Koch M, Capurso L, Dezi A, Ferrario F, Scarpignato C. Prevention of NSAID-induced gastroduodenal mucosal injury: metaanalysis of clinical trials with misoprostol and H2-receptor antagonists. Dig Dis 1995;1:62-74.
62. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, Stanton DS. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344-50.
63. Chan FK, Sung JJ, Ching JY, Wu JC, Lee YT, Leung WK, et al. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2001;15:19-24.
64. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Int Med 2002;162:169-75.
65. Chan FK, Chung SCS, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
66. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
67. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
68. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998;352:1016-21.
69. Langman MJS, Weil J, Wainwright, Lawson DH, Rawlins MD, Logan RFA, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8. (Erratum, Lancet 1994;343:1302).
70. Lanas A, Bajador E, Serrano P, Fuentes J, Careno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs and the risk of upper gastrointestinal bleeding. New Engl J Med 2000;343:834-9.
71. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
72. Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984;2:1171-4.
73. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480-9.
74. Morris AJ, Wasson LA, MacKenzie. Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut 1992;33:887-9.
75. Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J 1985;290:347-9.
76. Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjamason I. Diaphragm disease: pathology of disease of the small intestine induced by non steroidal anti-inflammatory drugs. J Clin Pathol 1988;41:516-26.
77. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by non-steroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992;152:625-32.
78. Etienney I, Beaugerie L, Viboud C, Flahault A. Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut 2003;52:260-3.
79. Halter F, Weber B, Huber T, Eigenman F, Frey MP, Ruchti C. Diaphragm disease of the ascending colon. Association with sustained-released diclofenac. J Clin Gastroenterol 1993;16:74-80.
80. De Parades V, Sultan S, Bauer P. Complications ano-rectales et coliques des suppositoires et des lavements. Gastroenterol Clin Biol 1996;20:446-52.
81. Colin R, Hochain P, Czernichow P, Petit A, Manchon ND, Berkelmans I. Non-steroidal anti-inflammatory drugs and segmental non-gangrenous colitis: a case-control study. Eur J Gastroenterol Hepatol 1993;5:715-9.
82. Campbell K, Steele RJC. Non-steroidal anti-inflammatory drugs complicated diverticular disease: a case-control study. Br J Surg 1991;78:190-1.
83. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Int Med 1987;107:513-6.
84. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619-22.
85. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95:1949-54.
86. Bonner GF, Walczak M, Kitchen L, Bayonna M. Tolerance of nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2002;95:1946-8.
87. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in twoplacebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
88. Clemett D, Goa KL. Celecoxib. A review of its use in osteoarthritis rheumatoid arthritis and acure pain. Drugs 2000;59:957-80.
89. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13:761-7.
90. Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR. Review article: the gastrointestinal safety profile of rofecoxib a highly selective inhibitor of cyclooxygenase-2 in humans. Aliment Pharmacol Ther 2001;15:1-9.
91. Kivitz A, Eisen G, Zhao WW, Recker DP, Verburg KM. the COX-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration. Arthritis Rheum 2001;44(suppl 9):S136.
92. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
93. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
94. Goldstein JL, Stenson W, Agrawal N, Eisen G, Omachi J, Kent J, et al. Valdecoxib is associated with a significantly lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID. Gastroenterology 2002;98:A-469.
95. Harper S, Lee M, Curtis S, Ng J, Watson DJ, Bolognese J. A lower inicidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etericoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 2001;44(Suppl 9):S318.
96. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000;284:1247-55.
97. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rhumatoid arthritis. N Engl J Med 2000;343:1520-8.
98. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ 2002;324:1287-8.
99. Witter J. Medical officer review. www.fda.gov/ohrms/dockets/ac/01/briefing/367761_03_med.pdf (accès le 12 janvier 2003).
100. Goldkind L. Gastrointestinal Review Highlights of the CLASS Study. www.fda.gov/ohrms/dockets/ac/01/slides/3677s1_03_goldkind.ppt (accès le 12 janvier 2003).
101. Lu HL. Statistical Reviewer Briefing Document for the Advisory Committee. www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.pdf (accès le 12 janvier 2003).
102. Targum SL. Consultation NDA 21-042, S-007. Review of cardiovascular safety database. www.fda.gov/ohrms/dockets/ac/01/briefing/367762_06_cardio.pdf (accès le 12 janvier 2003).
103. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
104. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX-2): the human pharmacology of a selective inhibitor of COX2. Proc Natl Acad Sci USA 1999;96:272-7.
105. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
106. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonists delays healing in mice. Gastroenterology 1997;112:387-97.
107. Tatsuguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, et al. Localisation of cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000;46:782-9.
108. Sighthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-32.
109. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996;98:2076-85.
110. Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 2000;12:223-31.
111. Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol 2001;96:1306-8.
112. Mahadevan U, Loftus EV, Tremaine WJ, Sandbom WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002;97:910-4.
113. Bonner GF. Using COX-2 inhibitors in IBD: antiinflammatories inflame a controversy. Am J Gastroenterol 2002;97:784-5.